These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 28635863)
1. [Modern approaches to treatment of psychosis in Parkinson's disease]. Cozac VV Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):103-109. PubMed ID: 28635863 [TBL] [Abstract][Full Text] [Related]
3. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis. Wilby KJ; Johnson EG; Johnson HE; Ensom MHH Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039 [TBL] [Abstract][Full Text] [Related]
4. [Pimavanserin: a new treatment for the Parkinson's disease psychosis]. Duits JH; Ongering MS; Martens HJM; Schulte PFJ Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354 [TBL] [Abstract][Full Text] [Related]
5. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863 [TBL] [Abstract][Full Text] [Related]
6. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios. Hubbard D; Hacksell U; McFarland K Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614 [TBL] [Abstract][Full Text] [Related]
7. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis. Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395 [No Abstract] [Full Text] [Related]
9. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
10. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
11. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. Parsa MA; Bastani B J Neuropsychiatry Clin Neurosci; 1998; 10(2):216-9. PubMed ID: 9608412 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin as treatment for Parkinson's disease psychosis. Fox SH Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566 [No Abstract] [Full Text] [Related]
13. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Frieling H; Hillemacher T; Ziegenbein M; Neundörfer B; Bleich S Eur Neuropsychopharmacol; 2007 Feb; 17(3):165-71. PubMed ID: 17070675 [TBL] [Abstract][Full Text] [Related]